Safety Evaluation Study for Patients With Aggressive NK-cell Leukemia

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

September 21, 2023

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2026

Conditions
Aggressive NK Cell Leukemia
Interventions
DRUG

PPMX-T003

The therapeutic agent is administered continuously intravenously

Trial Locations (1)

734-8551

RECRUITING

Hiroshima University Hospital, Hiroshima

All Listed Sponsors
collaborator

Kyoto University Hospital

OTHER

collaborator

Hokkaido University Hospital

OTHER

collaborator

Okayama University

OTHER

collaborator

Tokai University

OTHER

collaborator

Kyushu University

OTHER

collaborator

Tohoku University

OTHER

collaborator

Nagoya University

OTHER

collaborator

Komagome Hospital

OTHER

lead

Hiroshima University Hospital

OTHER